Format

Send to

Choose Destination
Mult Scler. 2017 Jan;23(1):114-118. doi: 10.1177/1352458516640609. Epub 2016 Jul 11.

Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?

Author information

1
Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
2
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

BACKGROUND:

Multiple sclerosis (MS) patients are at risk of renewed disease activity after discontinuing natalizumab (NAT) treatment.

OBJECTIVE:

Assessing the implication of T helper 17 (Th17) cells in MS reactivation after NAT cessation.

METHODS:

We monitored frequencies of Th17 cells and interleukin (IL)-17 cytokine levels in blood samples of 57 MS patients, without, during, and after NAT exposure.

RESULTS:

Frequencies of both Th17 cells and, in part, also IL-17 levels, in peripheral blood increased under prolonged NAT therapy, returned to baseline after NAT withdrawal and became almost undetectable in blood samples of individuals who experienced relapses during the wash-out phase.

CONCLUSION:

Assessing the Th17-cell/IL-17 axis might help to predict rebound MS activity after NAT withdrawal.

KEYWORDS:

Multiple sclerosis; Th17 effector T cells; natalizumab; rebound effect; wash-out phase

PMID:
27003947
DOI:
10.1177/1352458516640609
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center